Investor Ideas Adds Nasdaq
IPO’s in Biotech ( $LEGN, $LTRN, $AMTI, $CALT, $RPRX, $PCVX) and Tech ( $UCL, $VRM)
Point Roberts WA, Delta BC, June 26, 2020 –
(Investorideas.com Newswire) Investorideas.com, a global news source and
leading investor resource announces its weekly roundup of stocks added to its
global stock directories, including biotech and tech.
This week’s new biotech companies are involved in
oncology, autoimmune and renal diseases and novel vaccinations.
The latest tech companies include an e-commerce
site for automobiles and a telecom data firm from China.
Lantern Pharma Inc. (NasdaqGS:LTRN) is a clinical-stage
biopharmaceutical company innovating the repurposing, revitalization and
development of precision therapeutics in oncology. We leverage advances in
machine learning, genomics, and artificial intelligence by using a proprietary
A.I. platform to discover biomarker signatures that help identify patients more
likely to respond to our pipeline of cancer therapeutics. Lantern’s focus is to
improve the outcome for patients by leveraging our technology to uncover,
rescue and develop abandoned or failed drugs. Our current pipeline of three
drugs, two in clinical stages and one in preclinical, focuses on cancers that
have unique and unmet clinical needs with a clearly defined patient population.
We believe that the use of machine learning, genomics and computational methods
can help accelerate the revitalization, refocusing and development of small molecule-based
therapies. By targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug, this approach
represents the potential to deliver best-in-class outcomes. Our team seeks out
experienced industry partners, world-class scientific advisors, and innovative
clinical-regulatory approaches to assist in delivering cancer therapies to
patients as quickly and efficiently as possible.
Legend Biotech Corporation (NasdaqGS:LEGN) is a global clinical-stage biopharmaceutical
company engaged in the discovery and development of novel cell therapies for
oncology and other indications. Our team of over 650 employees across the
United States, China and Europe, along with our differentiated technology,
global development, and manufacturing strategies and expertise, provide us with
the strong potential to discover, develop, and manufacture best-in-class cell
therapies for patients in need. We are engaged in a strategic collaboration
with Janssen Biotech to develop and commercialize our lead product candidate,
LCAR-B38M/JNJ-4528, an investigational BCMA-targeted CAR-T cell therapy for
patients living with relapsed or refractory multiple myeloma. This candidate is
currently being studied in registrational clinical trials.
Applied
Molecular Transport Inc. (NasdaqGS:AMTI) is a clinical-stage biopharmaceutical company
leveraging its proprietary technology platform to design and develop a pipeline
of novel oral biologic product candidates to treat autoimmune, inflammatory,
metabolic, and other diseases. AMT’s proprietary technology platform allows it
to exploit existing natural cellular trafficking pathways to facilitate the
active transport of therapeutic payloads across the intestinal epithelium (IE)
barrier. Active transport is an efficient mechanism that uses the cell’s own
machinery to transport materials across the IE barrier. AMT believes that its
ability to exploit this mechanism is a key differentiator of its approach. AMT
is developing oral biologic product candidates in patient-friendly tablet and
capsule forms that are designed for either targeting local gastrointestinal
(GI) tissue or entering systemic circulation to precisely address the relevant
biology of a disease. AMT is building a portfolio of oral product candidates
based on its technology platform including its lead product candidate, AMT-101,
an oral GI-selective interleukin 10 that has completed a Phase 1b clinical
trial in patients with ulcerative colitis (UC). AMT further plans to initiate
Phase 2 clinical trials of AMT-101 in UC and related inflammatory indications.
AMT’s technology platform enables it to design and develop various oral
biologic therapeutic modalities, such as peptides, proteins, full-length
antibodies, antibody fragments, and RNA therapeutics, with potentially
significant advantages over existing marketed and development-stage drugs.
Calliditas Therapeutics AB (NasdaqGS:CALT) is a specialty pharmaceutical company based in
Stockholm, Sweden. It is focused on developing high quality pharmaceutical
products for patients with a significant unmet medical need in niche
indications, in which Calliditas can partially or completely participate in the
commercialization efforts. Calliditas is focused on the development and
commercialization of the product candidate Nefecon, a unique two step
formulation optimized to combine a time lag effect with a concentrated release
of the active substance budesonide, within a designated target area. This
patented, locally acting formulation is intended for treatment of patients with
the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a
global Phase 3 study within IgAN and aims to commercialize Nefecon in the
United States.
Royalty Pharma plc (NasdaqGS::RPRX) Founded in 1996, Royalty Pharma is a leading
funder of innovation across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and not-for-profits
through small and mid-cap biotechnology companies to leading global pharmaceutical
companies. Royalty Pharma has assembled a portfolio of royalties which entitles
it to payments based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the biopharmaceutical
industry both directly and indirectly - directly when it partners with
companies to co-fund late-stage clinical trials and new product launches in
exchange for future royalties, and indirectly when it acquires existing
royalties from the original innovators. Royalty Pharma’s current portfolio
includes royalties on more than 45 commercial products, including AbbVie and
J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s
HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko
and Trikafta, and three development-stage product candidates.
Vaxcyte, Inc. (NasdaqGS:PCVX) formerly known as SutroVax, is a next-generation
vaccine company seeking to improve global health by developing superior and
novel vaccines designed to prevent or treat some of the most common and deadly
infectious diseases worldwide. The Company’s cell-free protein synthesis
platform, comprising the XpressCFTM platform, exclusively licensed from Sutro
Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the
design and production of protein carriers and antigens, the critical building
blocks of vaccines, in ways that the Company believes conventional vaccine
technologies currently cannot. In addition to its pneumococcal conjugate
vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its
proprietary platform to advance other novel vaccines, including a prophylactic
vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine
to treat periodontal disease (VAX-PG).
uCloudlink
Group Inc. (NasdaqGM:UCL) is the world’s first and leading mobile data
traffic sharing marketplace, according to Frost & Sullivan, pioneering the
sharing economy business model for the telecommunications industry. The
Company’s products and services deliver unique value propositions to mobile
data users, handset and smart-hardware companies, mobile virtual network
operators (MVNOs) and mobile network operators (MNOs). Leveraging its
innovative cloud SIM technology and architecture, the Company has redefined the
mobile data connectivity experience by allowing users to gain access to mobile
data traffic allowance shared by network operators on its marketplace, all
while providing reliable connectivity, high speeds and competitive pricing.
Vroom, Inc. (NasdaqGS:VRM) is an innovative, end-to-end ecommerce platform
designed to offer a better way to buy and a better way to sell used vehicles.
The company's scalable, data-driven technology brings all phases of the vehicle
buying and selling process to consumers wherever they are and offers an
extensive selection of vehicles, transparent pricing, competitive financing,
and contact-free, at-home pick-up and delivery.
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
About
Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a
recognized news source publishing third party news and press releases, research
and our own original financial content. We were one of the first retail
investor sites to cover renewable energy and cleantech stocks at
investorideas.com and our domain Renewableenergystocks.com. We were also one of
the most well- known and cited defense stock sites, featuring our domain
Homelanddefensestocks.com at its peak.
We follow the money for
investors as sector sentiment shifts and technology disrupts. Our mission is to
provide investor ideas with breaking news, resources, industry articles and
interviews with leading experts.
Learn about investing in
stocks and sector trends with our news alerts, articles, podcasts and videos, looking
at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable
energy and more. Investor Idea's original branded content includes the following
podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis
News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.
Public companies within the
sectors we cover use our news and content services to tell their story to interested investors.
Paid for content is disclosed.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure is posted for each compensated news release, content published
/created if required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news
services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media
services at Investorideas.com
Contact
Investorideas.com
800 665 0411
No comments:
Post a Comment